Cannabis and schizophrenia

John Rathbone*, Hannele Variend, Hetal Mehta

*Corresponding author for this work

Research output: Contribution to journalReview articleResearchpeer-review

30 Citations (Scopus)

Abstract

Background: Many people with schizophrenia use cannabis and its effects on the illness are unclear. Objectives: To evaluate the effects of cannabis use on people with schizophrenia and schizophrenia-like illnesses. Search strategy: We searched the Cochrane SchizophreniaGroup Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. Selection criteria: We included all randomised trials involving cannabinoids and people with schizophrenia or schizophrenia-like illnesses. Data collection and analysis: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95%confidence intervals (CI) on an intention-to-treat basis, based on a fixed effectsmodel.We calculated the numbers needed to treat/harm(NNT/NNH). For continuous data, we calculated weighted mean differences (WMD) again based on a fixed effects model. Main results: We identified one randomised trial. No significant differences were found between the Cannabis and Psychosis Therapy (CAP) intervention group and the Psychoeducaton (PE) intervention for use of cannabis at threemonths assessment (n=47, RR 1.04 CI 0.6 to 1.7). BPRS-extended scale scores at three months assessment (n=47, WMD -3.60 CI -12.8 to 5.6) and nine months assessment (n=47, WMD 0.80 CI -7.5 to 9.1) were non-significant between CAP and PE. We found no significant improvement in social functioning in the CAP group compared with PE (at 3 months, n=47, WMD -0.80 CI -10 to 8.4) and (at 9 months, n=47, WMD -4.70 CI -14.5 to 5.1). Authors' conclusions: At present, there is insufficient evidence to support or refute the use of cannabis/cannabinoid compounds for people suffering with schizophrenia. This review highlights the need for well designed, conducted and reported clinical trials to address the potential effects of cannabis based compounds for people with schizophrenia.

Original languageEnglish
Article numberCD004837
JournalCochrane Database of Systematic Reviews
Volume2008
Issue number3
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Dive into the research topics of 'Cannabis and schizophrenia'. Together they form a unique fingerprint.

Cite this